Vertex Pharmaceuticals Inc (Vertex) develops transformative medicines for people with serious and life-threatening diseases. The company operates through one segment, Pharmaceuticals. It also generates revenue from royalties and collaborations. The company focuses its R&D on the discovery and development of drugs for cystic fibrosis and other serious diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Through R&D efforts, the company strives to discover and develop new drugs for cystic fibrosis. It also has several ongoing research programs with focus on the underlying mechanisms of other serious diseases including cystic fibrosis, pain, kidney diseases, beta thalassemia, sickle cell, duchenne muscular dystrophy and type -1 diabetes disease. Collaborates with biopharmaceutical and technology companies, government laboratories, leading academic research institutions, foundations and other organizations. Owns issued patents and pending patent applications in the US and foreign countries It has R&D centers and commercial offices in the US, Europe, Canada and Australia. In FY2023, the company incurred R&D expenses of US$3,690 million, which as a percentage of revenue stood at 37.3%.